World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025

LONDON, July 30, 2015 /PRNewswire/ --

Cancer Treatments - Your New Guide to that Market, its R&D and Sales Potentials
Do you want to assess the future of cancer-treating medicines? Visiongain's new report gives you revenue predictions for that industry from 2015, helping you stay ahead. There you discover financial data, R&D trends, opportunities, interviews and revenue forecasts.

In our analysis you see forecasted sales to 2025 at overall world market, submarket, product and national level. You assess emerging trends, technologies and branded therapies. With our study, benefit your research, analysis, decisions, presentations and influence.

Events shaping that crucial pharma industry - cancer remains a top priority for healthcare
Discover in our work what the future holds for cancer medicines. Those treatments become ever more important to pharmaceutical companies. Discover why, seeing what shapes that industry. Explore prospects from 2015 for that technology and business.

That way you assess how patients, treatment providers and drug producers stand to benefit from 2015 to 2025. Our study predicts high, rising spending on cancer-treating products. Stay ahead, then, in knowledge to benefit your work.

Please read on now to examine the anti-cancer drugs industry. Also see, below, how high that market's future revenues could go.

Forecasts from 2015 and other analyses show you therapies' sales potentials
Is finding data for cancer treatment a challenge? Reduce time spent getting information. Our work shows the most promising and lucrative parts of applied oncology.

Besides revenue forecasting to 2025, our study reveals historical data, growth rates and market shares. You assess quantitative and qualitative analyses, commercial news, outlooks and developments (R&D). In addition, you gain 122 tables, 137 charts and two interviews.

To see a report overview please email Sara Peerun on [email protected]

Avoid missing out. The purpose of our analysis is to help you stay ahead in knowledge and benefit your authority on the potential of cancer-treating drugs.

Many opportunities remain for those treatments. Now see how you can benefit your research, analyses and decisions on those medicines, including biological drugs (biologics).

The following sections show how our new investigation helps your work. Discover there how you could benefit your reputation for technological and commercial insight.

Outlooks for the world cancer drugs market and segments - what sales are possible?
Along with prediction of overall world market value to 2025, our report shows you individual revenue forecasting of four therapeutic submarkets at world level:

• Immunotherapy
• Chemotherapy
• Targeted treatments
• Hormone-based therapy

Our study also discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your company to develop. You assess leading brands too.

Forecasts for 25 leading drugs and 15 emerging medicines - discover selling potentials
How will leading drugs perform to 2025 at world level? Our study predicts individual revenues of the top 25 anti-cancer agents from 2015, including these products:

• Avastin
• Herceptin
• Rituxan/MabThera
• Gleevec/Glivec
• Revlimid
• Alimta
• Velcade
• Erbitux

You also discover individual selling potentials of 15 emerging therapies, recently approved, including these agents:

• Farydak
• Ibrance
• Lenvima
• Opdivo
• Unituxin
• Beleodaq
• Cyramza
• Imbruvica

There, in our analyses, you see how high sales can go, to 2025, finding drugs and years with highest predicted growth and revenues. You examine what's happening, understanding trends, competition, challenges and opportunities. That information helps you compete.

Our new survey also shows geographical revenue predictions, a breakdown of our overall world market forecast.

Leading national markets - where can highest revenues and growth occur?
Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharma companies will occur from 2015. Our study shows you the most promising countries for revenues and sales growth.

There you gain individual revenue forecasts to 2025 for 11 national markets:

• United States (US)
• Japan
• Germany, France, United Kingdom (UK), Italy and Spain (the EU5 group)
• Brazil, Russia, India and China (BRIC nations)

Our analyses show sales growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2015 to 2025 will change medical prescribing and the commercial landscape.

Discover, too, where R&D in oncology heads.

Research and development - assess innovation, trends and possibilities
What's happening in oncological R&D? Our study reveals and explains trends for treating cancers. That way you explore drug development in these fields of oncology, by cancer type:

• Breast
• Prostate
• Lung
• Intestinal
• Cervix
• Stomach
• Liver

To see a report overview please email Sara Peerun on [email protected]

Our work also discusses products in development for these cancers, including progress in clinical trials:

• Ovary
• Bladder
• Kidney
• Pancreas
• Non-Hodgkin's lymphoma
• Leukaemia

R&D in oncology holds strength, variety and promise. You assess innovations for treating those diseases, hearing about developments and finding their significance. Our study shows you what's possible to benefit patients, healthcare providers and pharmaceutical companies.

For large firms and specialty pharma there exist many opportunities. Our study explains, discussing issues to help your work. Examine changes shaping that market from 2015.

Forces changing the industry and market for cancer-treating medicines
Our new report discusses issues and events from 2015 that affect companies in the market, including these influences:

• Rising incidence of cancers - increasing demand for existing and new anti-cancer medicines
• Monoclonal antibodies (mAbs), cancer vaccines and non-specific immunotherapies
• Targeted therapies and differentiating agents
• Challenges and opportunities of drug development - outlooks for the future.

Our survey discusses other aspects of cancer treatment, including these trends:

• Patent expiries and the impact of generics and biosimilars - rising competition, including the need for technological advances to help innovators stay ahead
• Extension of approved uses - the quest for new indications, further clinical testing
• Shifts towards personalised medicine - the applications of biomedical technologies
• Point-of-care and real time testing of tumours - advances in diagnostic tests.

With that analysis you explore technological, economic, social and political questions, assessing outlooks for developers, manufacturers and sellers. You also assess the cancer drug industry's strengths, weaknesses, opportunities and threats.

See what's possible for companies in that industry. What does their future hold?

Leading companies and 2019 market value
From 2015, new treatments hold great potential for investment, technological advances and high sales. Our analyses predict the world cancer drugs market will reach $124.9bn in 2019. Visiongain forecasts strong revenue expansion to 2025, with pharma companies benefiting.

To see a report overview please email Sara Peerun on [email protected]

Our analysis shows you what technologies, products and organisations hold greatest potential. That way you explore leading companies and their outlooks, including these firms:

• Roche
• Novartis
• Celgene
• Eli Lilly
• AstraZeneca
• Bristol-Myers Squibb
• Johnson & Johnson
• Merck & Co.

Prospects for R&D and sales in oncology are strong, and from 2015 there will arise many opportunities. See where. Our report shows you the possibilities, helping you succeed.

Seven ways World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 helps
In these seven main ways, our new analysis gives knowledge to make your work easier and faster, also benefiting your decisions:

• World market size to 2025 and revenues for 4 submarkets - assess outlooks for development, production, marketing and sales, seeing what's possible
• 25 leading drugs' and 15 emerging medicines' revenues to 2025 - find sales potentials for top brands, seeing how they can compete and succeed
• 11 national markets' forecasts to 2025 - investigate leading countries in the Americas, Europe and Asia for revenues and market expansion
• R&D by cancer type - explore progress in research and development, finding technological and medical possibilities, seeing potential new products
• Profiles of 8 companies - analyse leading participants' results, portfolios, capabilities, deals and outlooks
• Interviews with two other authorities - discover opinions to help you stay ahead
• Analysis of what stimulates and restrains the cancer treatments sector - assess challenges and opportunities, helping you gain advantages and succeed.

Knowledge found nowhere else, benefiting your influence in pharma biotechnology
Our work gives independent analysis. There you gain competitive intelligence found only in that report. You see where business prospects are most rewarding and promising.

That new report, by visiongain's UK-based in-house analysts, gives knowledge to benefit your research, analyses, plans, decisions and proposals. You get data leading companies depend on.

With our investigation you are less likely to fall behind in data or miss opportunity. Discover there, by your choice, how to save time and benefit your information searches. Also see how our analysis could benefit your reputation for technological and commercial insight.

Trying our report now lets you discover biopharma opportunities and forecasts
Our new report's purpose is to help professionals analysing cancer treatments. See what's possible for developers, producers and marketers. You find trends, opportunities and revenue predictions. So avoid missing out - please get that study here now.

To see a report overview please email Sara Peerun on [email protected]

Organisations Mentioned in the Report

AbbVie
Active Biotech
Advaxis
Alchemia
Allergan
American Cancer Society
Amgen
AmpImmune
Argos Therapeutics
ArQule
AstraZeneca
Barvarian Nordic
Bayer
Biothera
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Celator Pharmaceuticals
Celgene
Clovis Oncology
Cyclacel
Daiichi Sankyo
Dendreon
Dr. Reddy's Laboratories
Eisai
Eli Lilly
EMA
Sanofi
EMD Serono
European Commission
FDA
Galena Biopharma
Gilead
GSK
Heat Biologics
Immatics Biotechnologies
Infinity Pharmaceuticals
Inovio Pharmaceuticals
Janssen
Japanese MHLW
Jennerex Biotherapeutics
Jiangsu Hengrui Medicine
Johnson & Johnson
Massachusetts General Hospital
MedImmune
Merck & Co.
Merck KGaA
Merrimack
National Cancer Institute
National Comprehensive Cancer Network
Newlink
Novartis
OncoGenex
Onyx
Orion
OSi Pharmaceuticals
Petrov Institute of Oncology
Pfizer
Pharmacyclics
Progen Pharmaceuticals
Puma Biotechnology
Roche
Rose Li and Associates
Spectrum Pharmaceuticals
Spirogen
Sun Pharma
Sunesis Pharmaceuticals
Syndax
Takeda
Telomedix
TESARO
Teva Pharmaceuticals
Tracon Pharma
Transgene
United Therapeutics
Vaccinogen
Viventia Biotech
Xbiotech

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44(0)20-7336 6100

Or click on https://goo.gl/oLKezX

SOURCE Visiongain